Ken K. Tsang

Ken K. Tsang

Auto-generated profile, based on publicly available information

Ken K. Tsang

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Hong Kong Eye Hospital, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2025 in Acta Ophthalmologica
Verified
Journal Article
Open access
KTKen K. Tsang
Ken K. Tsang
VHVivian W. K. Hui
Vivian W. K. Hui
CPChristopher M. K. Pang
Christopher M. K. Pang
ZTZiqi Tang
Ziqi Tang
GYGabriel YANG
Gabriel YANG
SSSimon Ka Ho Szeto
Simon Ka Ho Szeto
Purpose: To investigate the role of spectral domain optical coherence tomography (SD‐OCT)‐based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti‐vascular endothelial growth factor (VEGF) therapy. Methods: Retrospective cohort study including consecutive cases of RVO associated MO who received anti‐VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD‐OCT‐based biomarkers, including vitreomacular status, size of intra‐retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper‐reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF). Results: One hundred and thirty eyes were included with 81 and 49 eyes in the BRVO and CRVO subgroup, respectively. In both subgroups, baseline disrupted EZ/ELM [BRVO: ( β = 0.144 p = 0.008; β = 0.111 p = 0.014; β = 0.096 p = 0.042) and CRVO: ( β = 0.316 p < 0.001; β = 0.336 p < 0.001; β = 0.327 p < 0.001)] were associated with worse VA from baseline through 24 months. In the BRVO subgroup, the presence of HRF ( β = 0.209 p < 0.001) correlated with worse baseline VA. Improvement in DRIL extent [OR = 4.355 (1.109–17.094) p = 0.035; OR = 4.510 (1.707–11.917) p = 0.002] and EZ/ELM integrity [OR = 4.474 (1.783–11.223) p = 0.001; OR = 3.214 (1.414–7.305) p = 0.005] were associated with a higher likelihood of achieving at least a 5 letters gain at 12 and 24 months. Conclusion: A comprehensive system of SD‐OCT‐based features could predict functional outcomes of MO secondary to RVO with anti‐VEGF therapy up to 24 months.


13 June 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
SSSimon Ka Ho Szeto
Simon Ka Ho Szeto
JLJulia T.W. Lam
Julia T.W. Lam
AYAmy H.Y. Yu
Amy H.Y. Yu
CPChristopher M.K. Pang
Christopher M.K. Pang
TLTimothy P.H. Lin
Timothy P.H. Lin
CTChi Wai Tsang
Chi Wai Tsang

7 May 2026 in Ophthalmology Retina
Verified
Journal Article
Closed access
SSSimon Ka Ho Szeto
Simon Ka Ho Szeto
AYAmy H.Y. Yu
Amy H.Y. Yu
VHVivian W.K. Hui
Vivian W.K. Hui
JLJulia T.W. Lam
Julia T.W. Lam
KTKen K. Tsang
Ken K. Tsang
CTChi Wai Tsang
Chi Wai Tsang